Paul W Hruz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3103238/publications.pdf

Version: 2024-02-01

57 papers	3,098 citations	172457 29 h-index	161849 54 g-index
59 all docs	59 docs citations	59 times ranked	3948 citing authors

#	Article	IF	Citations
1	The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy. Journal of Biological Chemistry, 2000, 275, 20251-20254.	3.4	507
2	Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. Science Signaling, 2016, 9, ra21.	3.6	223
3	Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. Aids, 2002, 16, 859-863.	2.2	203
4	Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. Hepatology, 2004, 40, 1322-1332.	7.3	200
5	Structural analysis of the GLUT1 facilitative glucose transporter. Molecular Membrane Biology, 2001, 18, 183-193.	2.0	142
6	HIV Protease Inhibitors Acutely Impair Glucose-Stimulated Insulin Release. Diabetes, 2003, 52, 1695-1700.	0.6	114
7	Indinavir Induces Acute and Reversible Peripheral Insulin Resistance in Rats. Diabetes, 2002, 51, 937-942.	0.6	93
8	SLC2A8 (GLUT8) is a mammalian trehalose transporter required for trehalose-induced autophagy. Scientific Reports, 2016, 6, 38586.	3.3	87
9	Delayed Hepatocellular Mitotic Progression and Impaired Liver Regeneration in Early Growth Response-1-deficient Mice. Journal of Biological Chemistry, 2004, 279, 43107-43116.	3.4	85
10	The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications. Toxicologic Pathology, 2009, 37, 65-77.	1.8	82
11	A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity. Journal of Biological Chemistry, 2004, 279, 55147-55152.	3.4	73
12	HIV Protease Inhibitors Act as Competitive Inhibitors of the Cytoplasmic Glucose Binding Site of GLUTs with Differing Affinities for GLUT1 and GLUT4. PLoS ONE, 2011, 6, e25237.	2.5	72
13	GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovascular Diabetology, 2012, 11, 63.	6.8	64
14	Liver regeneration is impaired in lipodystrophic fatty liver dystrophy mice. Hepatology, 2010, 52, 2109-2117.	7.3	63
15	Direct Comparison of the Acute In Vivo Effects of HIV Protease Inhibitors on Peripheral Glucose Disposal. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 398-403.	2.1	56
16	Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy. PLoS ONE, 2011, 6, e17178.	2.5	54
17	Effects of the HIV Protease Inhibitor Ritonavir on GLUT4 Knock-out Mice. Journal of Biological Chemistry, 2010, 285, 36395-36400.	3.4	53
18	Mammalian Glucose Transporter Activity Is Dependent upon Anionic and Conical Phospholipids. Journal of Biological Chemistry, 2016, 291, 17271-17282.	3.4	53

#	Article	IF	Citations
19	In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. Journal of Biological Chemistry, 2015, 290, 14441-14453.	3.4	52
20	Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice. Diabetes, 2009, 58, 1739-1748.	0.6	51
21	Cysteine-scanning Mutagenesis of Transmembrane Segment 7 of the GLUT1 Glucose Transporter. Journal of Biological Chemistry, 1999, 274, 36176-36180.	3.4	48
22	Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. American Journal of Physiology - Endocrinology and Metabolism, 2001, 280, E549-E553.	3.5	47
23	Rosiglitazone inhibits mouse liver regeneration. FASEB Journal, 2006, 20, 2609-2611.	0.5	47
24	Molecular mechanisms for insulin resistance in treated HIV-infection. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 459-468.	4.7	42
25	Cysteine-Scanning Mutagenesis of Transmembrane Segment 11 of the GLUT1 Facilitative Glucose Transporterâ€. Biochemistry, 2000, 39, 9367-9372.	2.5	37
26	HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Current Opinion in HIV and AIDS, 2008, 3, 660-665.	3.8	35
27	Acute Sulfonylurea Therapy at Disease Onset Can Cause Permanent Remission of KATP-Induced Diabetes. Diabetes, 2011, 60, 2515-2522.	0.6	33
28	Development of GLUT4-selective antagonists for multiple myeloma therapy. European Journal of Medicinal Chemistry, 2017, 139, 573-586.	5.5	31
29	3-Hydroxy-3-methylglutaryl coenzyme A lyase (HL): cloning and characterization of a mouse liver HL cDNA and subchromosomal mapping of the human and mouse HL genes. Mammalian Genome, 1993, 4, 382-387.	2.2	30
30	Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection. American Journal of Infectious Diseases, 2006, 2, 187-192.	0.2	28
31	Avian 3â€hydroxyâ€3â€methylglutarylâ€CoA lyase: Sensitivity of enzyme activity to thiol/disulfide exchange and identification of proximal reactive cysteines. Protein Science, 1992, 1, 1144-1153.	7.6	26
32	The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrobial Agents and Chemotherapy, 2015, 59, 6203-6209.	3.2	26
33	MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis. Scientific Reports, 2017, 7, 8400.	3.3	26
34	3-Hydroxy-3-methylglutaryl coenzyme A lyase: affinity labeling of the Pseudomonas mevalonii enzyme and assignment of cysteine-237 to the active site. Biochemistry, 1992, 31, 6842-6847.	2.5	25
35	HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB Journal, 2008, 22, 2161-2167.	0.5	25
36	TFEB-dependent induction of thermogenesis by the hepatocyte SLC2A inhibitor trehalose. Autophagy, 2018, 14, 1959-1975.	9.1	23

#	Article	IF	Citations
37	Lactotrehalose, an Analog of Trehalose, Increases Energy Metabolism Without Promoting Clostridioides difficile Infection in Mice. Gastroenterology, 2020, 158, 1402-1416.e2.	1.3	23
38	Expression, purification, and functional characterization of the insulinâ€responsive facilitative glucose transporter <scp>GLUT</scp>4. Protein Science, 2015, 24, 2008-2019.	7.6	19
39	Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering. PLoS ONE, 2019, 14, e0216457.	2.5	19
40	Isoform-selective Inhibition of Facilitative Glucose Transporters. Journal of Biological Chemistry, 2014, 289, 16100-16113.	3.4	16
41	A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters. Antimicrobial Agents and Chemotherapy, 2016, 60, 7407-7414.	3.2	16
42	Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria. Linacre quarterly, The, 2020, 87, 34-42.	0.2	14
43	Tipranavir Without Ritonavir Does Not Acutely Induce Peripheral Insulin Resistance in a Rodent Model. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 624-625.	2.1	12
44	Letter to the Editor: â€œEndocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guidelineâ€. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 686-687.	3.6	12
45	Saxagliptin improves glucose tolerance but not survival in a murine model of dilated cardiomyopathy. Cardiovascular Endocrinology, 2012, 1, 74-82.	0.8	11
46	3-Hydroxy-3-methylglutaryldithio-CoA: utility of an alternative substrate in elucidation of a role for HMG-CoA lyase's cation activator. BBA - Proteins and Proteomics, 1993, 1162, 149-154.	2.1	9
47	Acipimox, an Inhibitor of Lipolysis, Attenuates Atherogenesis in LDLR-Null Mice Treated With HIV Protease Inhibitor Ritonavir. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2028-2032.	2.4	9
48	Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia. Scientific Reports, 2018, 8, 6475.	3.3	8
49	GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose Homeostasis in Cultured Adipocytes or in a Healthy-Rodent Model System. Antimicrobial Agents and Chemotherapy, 2011, 55, 1377-1382.	3.2	6
50	Evaluating the Efficacy of GLUT Inhibitors Using a Seahorse Extracellular Flux Analyzer. Methods in Molecular Biology, 2018, 1713, 69-75.	0.9	6
51	Letter to the Editor from William J. Malone et al: â€œProper Care of Transgender and Gender-diverse Persons in the Setting of Proposed Discrimination: A Policy Perspectiveâ€. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3287-e3288.	3.6	4
52	HIV and Endocrine Disorders. Endocrinology and Metabolism Clinics of North America, 2014, 43, xvii-xviii.	3.2	3
53	Contribution of systemic inflammation to permanence of K_{ATP}-induced neonatal diabetes in mice. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E1121-E1132.	3.5	1
54	Experimental Approaches to Alleviating Gender Dysphoria in Children. The National Catholic Bioethics Quarterly, 2019, 19, 89-104.	0.0	1

#	Article	IF	Citations
55	Commentary. Clinical Chemistry, 2015, 61, 1444-1444.	3.2	0
56	Mo1528 GLUT8 (SLC2A8) Is a Mammalian Trehalose Transporter Required for Trehalose-Induced Autophagy. Gastroenterology, 2016, 150, S715.	1.3	0
57	The Use of Cross-Sex Steroids in the Treatment of Gender Dysphoria. The National Catholic Bioethics Quarterly, 2017, 17, 661-671.	0.0	0